AcuCort plans free issuance of warrants in SEK 70.3 million rights issue

• AcuCort set a rights issue of up to 78,148,177 units, each with 2 warrants of series TO 3 issued free.
• TO 3 warrants cover up to 156,296,354 new shares, potentially raising up to SEK 93.8 million before costs.
• Exercise window is event-driven on FDA approval for Zeqmelit®, starting no earlier than Dec. 30, 2026.
• If no FDA approval, TO 3 exercise runs March 1-14, 2028; strike set at 80% of VWAP with SEK 0.22-0.60 bounds.
• TO 3 admission to trading on Spotlight is planned around Dec. 21, 2026; final trading day no later than March 10, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202610050245BITN____UKPR__EN_20261004-BIT-8811-0) on October 05, 2026, and is solely responsible for the information contained therein.